CRISPR Loss-of-Function Screen Identifies the Hippo Signaling Pathway as the Mediator of Regorafenib Efficacy in Hepatocellular Carcinoma

Regorafenib is used for hepatocellular carcinoma (HCC), but its response does not last long, partly due to chemoresistance acquisition. We performed a clustered regularly interspaced short palindromic repeats (CRISPR)-based loss-of-function genetic screen and aimed to discover molecules involved in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Suemura, Shigeki, Kodama, Takahiro, Myojin, Yuta, Yamada, Ryoko, Shigekawa, Minoru, Hikita, Hayato, Sakamori, Ryotaro, Tatsumi, Tomohide, Takehara, Tetsuo
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6770429/
https://ncbi.nlm.nih.gov/pubmed/31540262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11091362
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados